U.S. Markets open in 2 hrs 3 mins
  • S&P Futures

    -5.00 (-0.15%)
  • Dow Futures

    -54.00 (-0.19%)
  • Nasdaq Futures

    -20.00 (-0.17%)
  • Russell 2000 Futures

    -3.60 (-0.22%)
  • Crude Oil

    -0.73 (-1.75%)
  • Gold

    +6.90 (+0.36%)
  • Silver

    +0.16 (+0.62%)

    +0.0032 (+0.2728%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.81 (+2.78%)

    +0.0105 (+0.8092%)

    -0.6160 (-0.5841%)

    +1,164.15 (+10.53%)
  • CMC Crypto 200

    +6.71 (+2.81%)
  • FTSE 100

    -65.08 (-1.11%)
  • Nikkei 225

    +72.42 (+0.31%)

The CEO, President & Director of RAPT Therapeutics, Inc. (NASDAQ:RAPT), Brian Wong, Just Bought A Few More Shares

Simply Wall St
·3 mins read

Even if it's not a huge purchase, we think it was good to see that Brian Wong, the CEO, President & Director of RAPT Therapeutics, Inc. (NASDAQ:RAPT) recently shelled out US$60k to buy stock, at US$30.06 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

See our latest analysis for RAPT Therapeutics

The Last 12 Months Of Insider Transactions At RAPT Therapeutics

Notably, that recent purchase by CEO, President & Director Brian Wong was not the only time they bought RAPT Therapeutics shares this year. Earlier in the year, they paid US$12.00 per share in a US$300k purchase. Even though the purchase was made at a significantly lower price than the recent price (US$28.75), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

RAPT Therapeutics insiders may have bought shares in the last year, but they didn't sell any. They paid about US$14.33 on average. To my mind it is good that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!


RAPT Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of RAPT Therapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. RAPT Therapeutics insiders own about US$21m worth of shares. That equates to 3.0% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At RAPT Therapeutics Tell Us?

It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of RAPT Therapeutics we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing RAPT Therapeutics. At Simply Wall St, we've found that RAPT Therapeutics has 4 warning signs (1 is potentially serious!) that deserve your attention before going any further with your analysis.

But note: RAPT Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.